Trial Participants as Research Investors
ARV-Based Prevention Research and Development Product Pipeline
The Px Wire centerspread from April-June 2013 Volume 6, No. 2 showcases the ARV-based HIV prevention pipeline from pre-clinical research to implementation projects.
Achieving the End: One Year and Counting
In AVAC Report 2012, Achieving the End: One Year and Counting we’ve identified five priorities for action.
Microbicide Clinical Trial Participants by Region
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the prominent role played by African trial participants in microbicide research.
Achieving the End
Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.
Cumulative number of male circumcisions performed from 2008 to 2011
From AVAC Report 2012, this graph shows the cumulative number of male circumcisions performed from 2008 to 2011.
The Geography of Microbicide Research in sub-Saharan Africa
This map from AVAC Report 2012 spotlights the countries hosting ring and gel microbicide trials in sub-Saharan Africa.
Follow-on trials based on RV144: Strategy includes development and research tracks
This graphic from AVAC Report 2012 shows several planned vaccine trials building on the results of the RV144 AIDS vaccine trial.
Neutralizing Antibodies: Research pathways in 2013 and beyond
There are multiple lines of inquiry stemming from the discovery of potent, broadly neutralizing antibodies that have been isolated from HIV-infected individuals. This graphic from AVAC Report 2012 presents two pathways exploring the use of BNAbs as an HIV prevention tool.
AVAC Playbook 2012-2013: Progress toward global goals
AVAC first published its Playbook of global goals for ending AIDS in late 2011. This infographic from the AVAC Report 2012 builds on the objectives from 2011 and identifies five priorities for action in 2013.